Illumina, Inc. (NASDAQ:ILMN) fell 5.3% on Thursday after an insider sold shares in the company. The stock traded as low as $209.48 and last traded at $209.54. 1,292,868 shares were traded during mid-day trading, an increase of 18% from the average session volume of 1,092,243 shares. The stock had previously closed at $221.20.
Specifically, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00. Following the completion of the sale, the executive vice president now owns 30,370 shares in the company, valued at approximately $6,240,427.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Oene Mark Van sold 1,250 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $207.76, for a total transaction of $259,700.00. Following the sale, the senior vice president now owns 11,691 shares of the company’s stock, valued at approximately $2,428,922.16. The disclosure for this sale can be found here. Insiders have sold a total of 118,922 shares of company stock valued at $26,245,549 in the last quarter. Corporate insiders own 0.89% of the company’s stock.
Several brokerages have commented on ILMN. Deutsche Bank set a $275.00 target price on shares of Illumina and gave the company a “buy” rating in a research report on Tuesday, January 16th. Cowen boosted their price target on shares of Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, January 22nd. Leerink Swann boosted their price target on shares of Illumina from $250.00 to $276.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Morgan Stanley boosted their price target on shares of Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a report on Wednesday, January 31st. Finally, BTIG Research reissued a “hold” rating on shares of Illumina in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $241.39.
The company has a debt-to-equity ratio of 0.42, a current ratio of 3.99 and a quick ratio of 3.55. The stock has a market cap of $32,870.00, a PE ratio of 44.05, a P/E/G ratio of 2.77 and a beta of 0.92.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The firm had revenue of $778.00 million for the quarter, compared to analysts’ expectations of $752.04 million. During the same period in the previous year, the firm posted $0.85 EPS. The company’s revenue for the quarter was up 25.7% on a year-over-year basis. equities research analysts expect that Illumina, Inc. will post 4.59 EPS for the current fiscal year.
Large investors have recently modified their holdings of the business. Axiom International Investors LLC DE lifted its position in Illumina by 60.9% during the 3rd quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock worth $37,142,000 after buying an additional 70,572 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Illumina in the 3rd quarter valued at about $577,000. Creative Planning raised its holdings in shares of Illumina by 9.8% in the 4th quarter. Creative Planning now owns 12,384 shares of the life sciences company’s stock valued at $2,706,000 after purchasing an additional 1,107 shares during the period. Gateway Investment Advisers LLC raised its holdings in shares of Illumina by 3.5% in the 4th quarter. Gateway Investment Advisers LLC now owns 95,711 shares of the life sciences company’s stock valued at $20,912,000 after purchasing an additional 3,202 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Illumina by 1,556.2% in the 2nd quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after purchasing an additional 310,084 shares during the period. 92.09% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Illumina (ILMN) Shares Down 5.3% on Insider Selling” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/02/10/illumina-ilmn-shares-down-5-3-on-insider-selling.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.